An update on the clinical use of repetitive transcranial magnetic stimulation in the treatment of depression.

Journal of Affective Disorders
Paul B Fitzgerald

Abstract

Repetitive transcranial magnetic stimulation (rTMS) is an increasingly used treatment for patients with depression. The use of rTMS in depression is supported by over 20 years of clinical trials. There has been a significant increase in knowledge around the use of rTMS in recent years. The aim of this paper was to review the use of rTMS in depression to provide an update for rTMS practitioners and clinicians interested in the clinical use of this treatment. A targeted review of the literature around the use of rTMS treatment of depression with a specific focus on studies published in the last 3 years. High-frequency rTMS applied to the left dorsolateral prefrontal cortex is an effective treatment for acute episodes of major depressive disorder. There are several additional methods of rTMS delivery that are supported by clinical trials and meta-analyses but no substantive evidence that any one approach is any more effective than any other. rTMS is effective in unipolar depression and most likely bipolar depression. rTMS courses may be repeated in the management of depressive relapse but there is less evidence for the use of rTMS in the maintenance phase. The science around the use of rTMS is rapidly evolving and there is a consi...Continue Reading

References

Jan 1, 1991·Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society·A T Barker
Mar 11, 1999·Biological Psychiatry·D E BohningM S George
Aug 24, 2000·The Journal of Neuropsychiatry and Clinical Neurosciences·F A KozelM S George
Jan 25, 2005·Neuron·Ying-Zu HuangJohn C Rothwell
Feb 18, 2005·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Paul Fitzgerald
Aug 8, 2006·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Paul B FitzgeraldZafiris J Daskalakis
Aug 17, 2006·The Australian and New Zealand Journal of Psychiatry·Paul B FitzgeraldJayashri Kulkarni
Sep 9, 2006·The International Journal of Neuropsychopharmacology·Paul B FitzgeraldZ Jeff Daskalakis
Dec 21, 2006·Psychological Medicine·Colleen K LooPerminder S Sachdev
Mar 6, 2007·The International Journal of Neuropsychopharmacology·Guohua XiaJoseph R Calabrese
Sep 21, 2007·The International Journal of Neuropsychopharmacology·Colleen K LooPhilip B Mitchell
Aug 16, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sarah H LisanbyMark S George
Oct 29, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Bernardo Dell'osso, A Carlo Altamura
Jan 16, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Paul B FitzgeraldZafiris J Daskalakis
Oct 17, 2009·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Simone RossiUNKNOWN Safety of TMS Consensus Group
Apr 8, 2010·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Mark SinyorAnthony Levitt
Jul 17, 2010·Brain Stimulation·Keith S GarciaMarty Caudle
Aug 25, 2010·Depression and Anxiety·Paul E HoltzheimerCharles M Epstein
Jun 12, 2012·Brain Stimulation·Paul B FitzgeraldZafiris J Daskalakis
Sep 15, 2012·Brain Stimulation·Jonathan Downar, Z Jeff Daskalakis
Nov 3, 2012·Neuropsychiatric Disease and Treatment·Martin Luiz MyczkowskiMarco Antônio Marcolin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.